UPDATE 2-High-profile Bristol cancer drug disappoints, shares off

April 28 (Reuters) - Bristol-Myers Squibb Co on Tuesday reported first-quarter sales of its new cancer immunotherapy Opdivo that were about half of those for a rival medicine from Merck & Co, and its...